Literature DB >> 33772461

Efficient Generation of Functional Hepatocytes from Human Induced Pluripotent Stem Cells for Disease Modeling and Disease Gene Discovery.

Satish Kumar1, Joanne E Curran2, Sarah Williams-Blangero3,2, John Blangero2.   

Abstract

In vitro hepatocyte cell models are being used to study the pathogenesis of liver disease and in the discovery and preclinical stages of drug development. The culture of hepatic cell lines and primary hepatocytes as in vitro cell models has been carried out for several decades. However, hepatic cell lines (hepatic carcinoma generated or immortalized) have limited accuracy when recapitulating complex physiological functions of the liver. Additionally, primary hepatocytes sourced from human cadavers or medical biopsies are difficult to obtain due to sourcing limitations, particularly for large-scale population studies or in applications requiring large number of cells. Hepatocyte cultures differentiated from human embryonic stem cells (ESCs) and induced pluripotent stem cell (iPSCs) overcome in large part the limitations of traditional hepatocyte in vitro models. In this chapter, we described an efficient protocol routinely used in our laboratory to differentiate human iPSCs into functional hepatocyte cultures for in vitro modeling of liver function and disease. The protocol uses a three-stage differentiation strategy to generate functional hepatocytes from human iPSCs. The differentiated cells show characteristic hepatocyte morphology including flat and polygonal shape, distinct round nuclei, and presence of biliary canaliculi and they express hepatic markers alpha-fetoprotein (AFP), albumin (ALB), E-cadherin (CHD1), hepatocyte nuclear factor 4 alpha (HNF4α), and actin.
© 2021. Springer Science+Business Media, LLC.

Entities:  

Keywords:  Hepatocyte differentiation; Human; In vitro cell model; Induced pluripotent stem cell; Liver disease genetics; Liver toxicity and disease

Mesh:

Year:  2022        PMID: 33772461     DOI: 10.1007/7651_2021_375

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  14 in total

Review 1.  A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity.

Authors:  Anna Astashkina; Brenda Mann; David W Grainger
Journal:  Pharmacol Ther       Date:  2012-01-10       Impact factor: 12.310

Review 2.  Induced Pluripotent Stem Cells in Disease Modeling and Gene Identification.

Authors:  Satish Kumar; John Blangero; Joanne E Curran
Journal:  Methods Mol Biol       Date:  2018

3.  Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells.

Authors:  Sébastien Anthérieu; Alexandra Rogue; Bernard Fromenty; André Guillouzo; Marie-Anne Robin
Journal:  Hepatology       Date:  2011-05-02       Impact factor: 17.425

Review 4.  Cell lines: a tool for in vitro drug metabolism studies.

Authors:  M T Donato; A Lahoz; J V Castell; M J Gómez-Lechón
Journal:  Curr Drug Metab       Date:  2008-01       Impact factor: 3.731

Review 5.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

6.  Immortalized Human Hepatic Cell Lines for In Vitro Testing and Research Purposes.

Authors:  Eva Ramboer; Tamara Vanhaecke; Vera Rogiers; Mathieu Vinken
Journal:  Methods Mol Biol       Date:  2015

7.  Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.

Authors:  Ahmad Sharanek; Audrey Burban; Matthew Burbank; Rémy Le Guevel; Ruoya Li; André Guillouzo; Christiane Guguen-Guillouzo
Journal:  Sci Rep       Date:  2016-05-12       Impact factor: 4.379

Review 8.  Advances in Engineered Liver Models for Investigating Drug-Induced Liver Injury.

Authors:  Christine Lin; Salman R Khetani
Journal:  Biomed Res Int       Date:  2016-09-20       Impact factor: 3.411

Review 9.  Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies.

Authors:  Gregory H Underhill; Salman R Khetani
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-12-06

10.  Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions.

Authors:  Cuiping Pan; Chanchal Kumar; Sebastian Bohl; Ursula Klingmueller; Matthias Mann
Journal:  Mol Cell Proteomics       Date:  2008-10-23       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.